CTOs on the Move

OmniSYS

www.omnisys.com

 
OmniSYS is a technology company with 25+ years of experience working with pharmacies, payers, providers and pharmaceutical manufacturers. We leverage this unique market insight along with our pharmacy workflow expertise to deliver valuable solutions that help pharmacies thrive in the changing pharmacy landscape. Our solutions help pharmacies engage patients, grow clinical services and improve financial performance. OmniSYS currently serves over 25,000 pharmacies, connects to hundreds of payers and touches millions of patient lives.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.omnisys.com
  • 15950 Dallas Parkway Suite 350
    Dallas, TX USA 75248
  • Phone: 214.459.2574

Executives

Name Title Contact Details

Similar Companies

Patterson Medical

Patterson Medical is a Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RTI Biologics, Inc.

RTI Biologics, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Lamprey Health Care

Lamprey Health Care- Nashua Center is a health center located in Nashua, New Hampshire. It is typically open 52 hours per week - which is more hours than most health centers. 

Focus Diagnostics

Focus Diagnostics is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Focus Diagnostics is based in Cypress, CA. You can find more information on Focus Diagnostics at www.focusdx.com

Discovery Laboratories Inc

Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.